期刊文献+

DDX5基因表达下调对胃癌细胞增殖、迁移及侵袭影响 被引量:4

Down-regulation of DDX5 inhibiting gastric cancer cell proliferation,migration and invasion
下载PDF
导出
摘要 目的探讨DDX5基因表达下调对胃癌细胞增殖、迁移和侵袭的影响。方法采用慢病毒介导的DDX5-shRNA下调人胃癌HGC-27细胞中DDX5的表达。实时荧光定量PCR和蛋白免疫印迹(Western blot)法验证下调效果。CCK8和平板克隆检测细胞增殖能力,Transwell检测细胞迁移和侵袭能力的改变。结果 DDX5-shRNA可有效下调人胃癌HGC-27细胞中DDX5的mRNA和蛋白质表达。DDX5表达下调后,人胃癌HGC-27细胞的增殖受到抑制,24、48、72 h细胞增殖能力较转染了control-shRNA的细胞分别降低25.0%、33.3%和44.6%;转染了control-shRNA的细胞和转染了DDX5-shRNA的细胞克隆形成的数目分别为(162.6±10.3)个和(68.7±11.2)个,两组间比较,差异有统计学意义(P<0.05);转染了control-shRNA的细胞和转染了DDX5-shRNA的细胞24 h迁移数目分别为(153.7±9.2)个和(78.0±6.7)个,两组间比较,差异有统计学意义(P<0.05);转染了control-shRNA的细胞和转染了DDX5-shRNA的细胞24 h侵袭数目分别为(83.7±12.8)个和(40.2±7.6)个,两组间比较,差异有统计学意义(P<0.05)。结论 DDX5表达下调可明显抑制人胃癌HGC-27细胞的增殖、迁移及侵袭,其有可能成为胃癌的治疗靶点。 Objective To investigate the effects of DDX5 down- regulation on gastric cancer cell proliferation,migration and invasion. Methods Lentivirus mediated shRNA were used to down-regulate the expression of DDX5 in human gastric cancer HGC-27 cells. Real-time fluorescent quantitative PCR and Western blot method were used to verify the down-regulation effect. CCK8 and colony formation assay were employed to examine cell proliferation. Transwell assay was performed to detect cell migration and invasion.Results DDX5-shRNA effectively inhibited both mRNA and protein expression of DDX5. DDX5-shRNA significantly suppressed cell proliferation. Cell proliferation was inhibited by 25. 0%,33. 3% and 44. 6% in 24,48,72 hours,compared with control-shRNA cells.Moreover,colony formation was also inhibited. The number of colonies in 24 hours was( 162. 6 ± 10. 3) and( 68. 7 ± 11. 2) in the control-shRNA and DDX5-shRNA group,respectively,the difference between the two groups had statistical significance( P〈0. 05). Furthermore,cell migration was also inhibited by DDX5 down-regulation. The number of migrated cells in 24 hours was( 153. 7 ± 9. 2) and( 78. 0 ± 6. 7) in the control-shRNA and DDX5-shRNA groups,respectively,the difference between the two groups had statistical significance( P〈0. 05). Finally,cell invasion was also reduced. The number of invaded cells in 24 hours was( 83. 7 ± 12. 8) and( 40. 2 ±7. 6) in the control and DDX5-shRNA groups,respectively,the difference between the two groups had statistically significance( P〈0. 05). Conclusion Down-regulation of DDX5 significantly inhibits the proliferation,migration and invasion of gastric cancer HGC-27 cells.
出处 《临床军医杂志》 CAS 2017年第1期16-19,23,共5页 Clinical Journal of Medical Officers
基金 北京医卫健康公益基金(YWKYQ2001) 军队医学科技青年培育计划(15QNP005)
关键词 DDX5 胃癌 增殖 迁移 侵袭 DDX5 Gastric cancer Proliferation Migration Invasion
  • 相关文献

参考文献1

二级参考文献108

  • 1Yi-LingLi,ZhongTian,Dong-YingWu,Bao-YuFu,YahXin.Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions[J].World Journal of Gastroenterology,2005,11(2):285-288. 被引量:34
  • 2Wei-Tien Tai,Ann-Lii Cheng,Chung-Wai Shiau,Hsiang-Po Huang,Jui-Wen Huang,Pei-Jer Chen,Kuen-Feng Chen.Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma[J].Journal of Hepatology.2011(5)
  • 3George R. Blumenschein,Gordon B. Mills,Ana M. Gonzalez-Angulo.Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy[J].Journal of Clinical Oncology.2012(26)
  • 4Yoon-Koo Kang,Kei Muro,Min-Hee Ryu,Hirofumi Yasui,Tomohiro Nishina,Baek-Yeol Ryoo,Yukimasa Kamiya,Shiro Akinaga,Narikazu Boku.A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer[J].Investigational New Drugs.2014(2)
  • 5Andrew S Giraud,Trevelyan R Menheniott,Louise M Judd.Targeting STAT3 in gastric cancer[J].Expert Opinion on Therapeutic Targets.2012(9)
  • 6Brendan D. Manning,Lewis C. Cantley.AKT/PKB Signaling: Navigating Downstream[J].Cell.2007(7)
  • 7Timothy Iveson,Ross C Donehower,Irina Davidenko,Sergey Tjulandin,Andrzej Deptala,Mark Harrison,Somanath Nirni,Kuntegowdanahalli Lakshmaiah,Anne Thomas,Yizhou Jiang,Min Zhu,Rui Tang,Abraham Anderson,Sarita Dubey,Kelly S Oliner,Elwyn Loh.Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study[J]. Lancet Oncology . 2014 (9)
  • 8Min Li,Huawen Sun,Lujun Song,Xiaodong Gao,Wenju Chang,Xinyu Qin.Immunohistochemical expression of mTOR negatively correlates with PTENexpression in gastric carcinoma[J]. Oncology Letters . 2012 (6)
  • 9Bin Zhang,Yan Yang,Xiaoting Shi,Wanyu Liao,Min Chen,Alfred Sze-Lok Cheng,Hongli Yan,Cheng Fang,Shu Zhang,Guifang Xu,Shanshan Shen,Shuling Huang,Guangxia Chen,Ying Lv,Tingsheng Ling,Xiaoqi Zhang,Lei Wang,Yuzheng Zhuge,Xiaoping Zou.Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial–mesenchymal transition[J]. Cancer Letters . 2014
  • 10Li Vivian Sze Wing,Wong Chi Wai,Chan Tsun Leung,Chan Agnes Sze Wah,Zhao Wei,Chu Kent-Man,So Samuel,Chen Xin,Yuen Siu Tsan,Leung Suet Yi.Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer . 2005

共引文献12

同被引文献30

引证文献4

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部